For research and educational purposes only. Not medical advice.
Glatiramer acetate Reference
Educational, not medical advice reference for Glatiramer acetate: Immune; regulatory status, evidence posture, source review, and schedule notes. Also known…
Reference summary
Glatiramer acetate is a label-verified random peptide copolymer with FDA Phase 3 evidence reducing relapse rates in relapsing-remitting MS. pepSmart surfaces label-reference content only.
- Categories
- Immune
- Aliases
- Copaxone, Glatopa, Copolymer-1, Cop-1
- Evidence posture
- human - Label warnings include immediate post-injection reaction (chest tightness, flushing, palpitations, anxiety, dyspnea, throat constriction, urticaria) and lipoatrophy / localized skin necrosis at injection sites. Reactions are typically transient and self-limited but can recur with subsequent injections.
- Regulatory status
- FDA-approved prescription medication (Copaxone, Glatopa). Initial US approval 1996 (20 mg/mL); 40 mg/mL three-times-weekly formulation approved 2014. Indicated for treatment of relapsing forms of multiple sclerosis - including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease - in adults. Random peptide copolymer of L-glutamic acid, L-alanine, L-tyrosine, and L-lysine. Prescription-only.
- Content review status
- label verified